Diagnostic utility of weight and body mass index is widely overestimated, and their use as health and wellness measures can be sources of iatrogenic harm.
AMA J Ethics. 2023;25(7):E540-544. doi:
10.1001/amajethics.2023.540.
Kimberly A. Singletary, PhD and Marshall H. Chin, MD, MPH
The Roadmap to Advance Health Equity offers specific, actionable antiracist payment reform strategies to help ensure that everyone can receive good health services and optimize their health.
AMA J Ethics. 2023;25(1):E55-65. doi:
10.1001/amajethics.2023.55.
Monitoring surgeons’ capacities over time are rooted in professional duties to protect patients’ safety. Aging surgeons should undergo assessments and be encouraged to stop practicing before their diminished skill becomes too risky.
AMA J Ethics. 2016;18(10):986-992. doi:
10.1001/journalofethics.2016.18.10.ecas2-1610.
AMA Journal of Ethics theme editor Natasha Dolgin, an MD/PhD candidate at the University of Massachusetts School of Medicine, interviewed Dorry Segev, MD, PhD, about organ allocation policy and geographic disparities in access, possible ways to maximize equity, and advice physicians should give their patients between policy changes.
Shelley Wall, MBChB, Nikki Allorto, MBChB, Ross Weale, MBBS, Victor Kong, PhD, and Damian Clarke, PhD
Caring for severe burn injuries in low- and middle-income countries requires making decisions about resource allocation given particular contextual factors.
AMA J Ethics. 2018;20(6):575-580. doi:
10.1001/journalofethics.2018.20.6.msoc1-1806.
Should a family’s ability to afford follow-up care for a child who needs “miracle surgery” play a role in the physician’s decision to operate? Would the answer change depending on the patient’s immigration status?
There are “push” factors such as poor working conditions, substandard facilities, unsafe conditions, and low income that discourage health professionals trained in Indian medical schools from staying in country.
A major contributor to the lack of medicines in developing countries is an intellectual property regime that allows proprietary drug companies with intellectual property monopolies to charge high prices and maximize profit.